Recovery

BPC-157

Body Protection Compound 157

BPC-157 is a 15-amino-acid synthetic peptide derived from a protein found in gastric juice. It is widely discussed for injury recovery, but it is not an FDA-approved drug and its human research is very limited.

Key facts

  • Commonly discussed for: tendon, ligament and gut healing.
  • Evidence (D): A 2025 systematic review found 35 preclinical studies and just 1 clinical study (a retrospective chart review of knee pain in 16 patients); the only other human report is a 2-person IV safety pilot. No randomized controlled human trial has been published.
  • FDA status: PCAC recommended. FDA moved BPC-157 off its Category 2 restricted list in April 2026, and on July 23, 2026 the PCAC voted 8-6 (1 abstention) to recommend it for the 503A Bulks List for ulcerative colitis. In a notice published Oct 30, 2026, HHS said it does not intend to take enforcement action against licensed pharmacies and physicians compounding it under set conditions while the FDA writes rules. That is interim enforcement discretion, not FDA approval, and the FDA had not proposed adding it to the list as of Nov 18, 2026.
  • Legitimate access: Prescription compounding under an interim HHS policy (not FDA-approved).
  • Last reviewed: October 1, 2026.

Read the deep dives

Sources